Examples of molecules that interfere with molecular interactions of sPLA2s already exist: an aptamer that binds to NCL, a disordered co-receptor protein of a snake venom sPLA2, preventing its internalization into the cell and protecting it from its toxic effects [68]; and pentapeptides, which mimic a central stretch (63–67 in Figure 2) of Group II sPLA2s, one of which, cyclic, is in clinical trial as a drug against prostate cancer [36,93]. The gene discussed is PLA2G2D; the disease is prostate cancer.